Neurology Minute

Anna Rehbein

  • 1 minute 44 seconds
    Long-Term Outcomes and Rehabilitation in Anti-NMDAR Encephalitis - Part 1

    In part one of this two-part series, Dr. Justin Abbatemarco and Dr. Maarten Titulaer discuss long-term cognitive and functional outcomes in patients with anti-NMDAR encephalitis and their implications for rehabilitation.

    Show reference:

    https://www.neurology.org/doi/pdf/10.1212/WNL.0000000000210109

    22 November 2024, 9:30 am
  • 3 minutes 20 seconds
    Myelitis Associated With Rheumatologic Disease - Part 2

    In part two of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss abandoning the term lupus myelitis and emphasize the importance of accurately naming and identifying each autoimmune condition.

    Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200329  

    21 November 2024, 9:30 am
  • 4 minutes 38 seconds
    Myelitis Associated With Rheumatologic Disease - Part 1

    In part one of this two-part series, Dr. Stacey Clardy and Dr. Elias Sotirchos discuss key features of inflammatory myelopathy in rheumatologic disease, helping to better characterize the underlying causes of lupus myelitis.

    Show reference: https://www.neurology.org/doi/10.1212/NXI.0000000000200329 

    20 November 2024, 9:30 am
  • 1 minute 30 seconds
    Could GLP-1 Receptor Agonists Reduce the Risk of Neurologic Disorders?

    Dr. Tesha Monteith discusses the Brain & Life article, “Could GLP-1 Receptor Agonists Reduce the Risk of Neurologic Disorders?” by Hallie Levine, available in the latest issue of Brain & Life or at brainandlife.org. 

    Show reference:

    https://www.brainandlife.org/articles/new-weight-loss-drugs-may-help-neurologic-disorders 

    19 November 2024, 9:30 am
  • 2 minutes 11 seconds
    CAA-RI and Biopsy-Positive Primary Angiitis of the CNS - Part 3

    In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how to differentiate between CAA-RI and PACNS.

    Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

    18 November 2024, 9:30 am
  • 1 minute 2 seconds
    The Placebo Effect

    Dr. Gregg Day and Dr. Kathryn T. Hall discuss the complexities of the placebo effect, its variability among patients, and the genetic factors that influence responses to placebo treatments. 

    15 November 2024, 9:30 am
  • 2 minutes 23 seconds
    CAA-RI and Biopsy-Positive Primary Angiitis of the CNS - Part 2

    In part two of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss the underlying pathophysiology and how to diagnose primary angiitis of the CNS in clinical practice.

    Show reference: https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

    14 November 2024, 9:30 am
  • 2 minutes 11 seconds
    CAA-RI and Biopsy-Positive Primary Angiitis of the CNS - Part 1

    In part one of this three-part series, Dr. Justin Abbatemarco and Dr. Ahmad Nehme discuss how cerebral amyloid angiopathy and CAA-RI present in clinical practice and how to make a diagnosis.

    Show reference:

    https://www.neurology.org/doi/abs/10.1212/WNL.0000000000209548 

    13 November 2024, 9:30 am
  • 4 minutes 28 seconds
    Lab Minute - Vitamin D

    Dr. Stacey Clardy discusses vitamin D in this lab minute.

    12 November 2024, 9:30 am
  • 4 minutes 28 seconds
    Could Reducing Environmental Toxins Help Mitigate the Risk for Parkinson’s Disease? Where the Evidence Is Leading

    Dr. Halley Alexander discusses the Neurology Today article, "Could Reducing Environmental Toxins Help Mitigate the Risk for Parkinson’s Disease? Where the Evidence Is Leading" by Gina Shaw, available in the November 7th issue of Neurology Today or at neurologytoday.com.

    Show reference:

    https://journals.lww.com/neurotodayonline/pages/articleviewer.aspx?year=2024&issue=11070&article=00001&type=Fulltext

    11 November 2024, 9:30 am
  • 1 minute 58 seconds
    Genetic Leukodystrophies Mimicking CNS Inflammation - Part 3

    In the final part of this three-part series, Dr. Justin Abbatemarco and Dr. Jennifer L. Orthmann Murphy highlight important indicators for when to suspect hereditary spastic paraplegia, as well as guidelines for testing and interpreting results. 

    Show references: https://www.neurology.org/doi/10.1212/NXG.0000000000200192  https://cshperspectives.cshlp.org/content/early/2024/08/10/cshperspect.a041457

    8 November 2024, 9:30 am
  • More Episodes? Get the App
© MoonFM 2024. All rights reserved.